Your browser doesn't support javascript.
loading
Neoantigen vaccine platforms in clinical development: understanding the future of personalized immunotherapy.
Supabphol, Suangson; Li, Lijin; Goedegebuure, S Peter; Gillanders, William E.
Afiliación
  • Supabphol S; Department of Surgery, Washington University School of Medicine, St Louis, MO, USA.
  • Li L; The Center of Excellence in Systems Biology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Goedegebuure SP; Department of Surgery, Washington University School of Medicine, St Louis, MO, USA.
  • Gillanders WE; Department of Surgery, Washington University School of Medicine, St Louis, MO, USA.
Expert Opin Investig Drugs ; 30(5): 529-541, 2021 May.
Article en En | MEDLINE | ID: mdl-33641576
ABSTRACT

INTRODUCTION:

Derived from genetic alterations, cancer neoantigens are proteins with novel amino acid sequences that can be recognized by the immune system. Recent evidence demonstrates that cancer neoantigens represent important targets of cancer immunotherapy. The goal of cancer neoantigen vaccines is to induce neoantigen-specific immune responses and antitumor immunity, while minimizing the potential for autoimmune toxicity. Advances in sequencing technologies, neoantigen prediction ?algorithms,? and other technologies have dramatically improved the ability to identify and prioritize cancer neoantigens. These advances have generated considerable enthusiasm for ?the ?development of neoantigen vaccines. Several neoantigen vaccine platforms are currently being evaluated in early phase clinical trials including the synthetic long peptide (SLP), RNA, dendritic cell (DC), and DNA vaccine platforms. AREAS COVERED In this review, we describe, evaluate the mechanism(s) of action, compare the advantages and disadvantages, and summarize early clinical experience with each vaccine platform. We provide perspectives on the future directions of the neoantigen vaccine field. All data are derived from PubMed and ClinicalTrials search updated in October 2020. EXPERT OPINION Although the initial clinical experience is promising, significant challenges to the success of neoantigen vaccines include limitations in neoantigen identification and the need to successfully target the immunosuppressive tumor microenvironment.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Asunto principal: Vacunas contra el Cáncer / Antígenos de Neoplasias / Neoplasias Límite: Animals / Humans Idioma: En Revista: Expert Opin Investig Drugs Asunto de la revista: TERAPIA POR MEDICAMENTOS Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Asunto principal: Vacunas contra el Cáncer / Antígenos de Neoplasias / Neoplasias Límite: Animals / Humans Idioma: En Revista: Expert Opin Investig Drugs Asunto de la revista: TERAPIA POR MEDICAMENTOS Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos